WO2009080023A1 - Chewing-gum comprimé contenant un peptide - Google Patents

Chewing-gum comprimé contenant un peptide Download PDF

Info

Publication number
WO2009080023A1
WO2009080023A1 PCT/DK2007/050198 DK2007050198W WO2009080023A1 WO 2009080023 A1 WO2009080023 A1 WO 2009080023A1 DK 2007050198 W DK2007050198 W DK 2007050198W WO 2009080023 A1 WO2009080023 A1 WO 2009080023A1
Authority
WO
WIPO (PCT)
Prior art keywords
tablet
chewing gum
compressed
peptide
agents
Prior art date
Application number
PCT/DK2007/050198
Other languages
English (en)
Inventor
Carsten Andersen
Per Pihlmann Isager
Original Assignee
Fertin Pharma A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fertin Pharma A/S filed Critical Fertin Pharma A/S
Priority to PCT/DK2007/050198 priority Critical patent/WO2009080023A1/fr
Priority to PCT/DK2008/000444 priority patent/WO2009080032A1/fr
Publication of WO2009080023A1 publication Critical patent/WO2009080023A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A61K9/0058—Chewing gums
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/005—Antimicrobial preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides

Definitions

  • Peptides with antimicrobial effects may e.g. be used as an alternative or a as a supplement to antibiotics and other antimicrobial agents.
  • antimicrobial peptides are usually administered intravenously, although other modes of administration have been suggested.
  • a chewing gum composition is the final formulation, which constitutes at least a part of the compressed chewing gum tablets ready for sale or use by the consumer.
  • a chewing gum composition may comprise a peptide, a taste masking agent, a pH controlling agent, sweetener and/or flavour and optionally other ingredients like colouring agents, enzymes, humectants, flavour enhancers, anti- caking agents etc.
  • the expression “chewing gum particles containing gum base” refers to particulated material of a chewing gum composition and is to be understood as any form of chewing gum particles containing a certain amount of gum base as described in detail below.
  • the chewing gum particles may be in any suitable form such as pellets, granules, agglomerates or powder.
  • the particles have been particulated prior to application.
  • Particulation may be in any form of "building up” particles from smaller primary particles into macro particles or in any form of "building down” from larger substances into macro particles. Any form of particulation may be applied, such as granulation, pelletizing, agglomeration, or any other suitable means for particulation, as described below.
  • the particles may also to be understood as macroparticles.
  • the compressed chewing gum tablet comprises one compressed module, i.e. the above-mentioned "first compressed module” is the only compressed module present in the tablet.
  • the second compressed module comprises compressed tablet material. Accordingly, it is also preferred that the first compressed module does not contain tablet material. Examples of useful tablet material are given infra.
  • the present invention concerns a compressed chewing gum composition
  • a compressed chewing gum composition comprising a first, a second and a third compressed module, wherein the first and third compressed module comprise chewing gum particles containing gum base, and wherein the second compressed module contains the at least one peptide.
  • the first and/or the third compressed module do not contain any peptide and the second compressed module does not contain any chewing gum particles containing gum base.
  • the second compressed module preferably comprises tablet material.
  • this particular embodiment corresponds to the situation where the first compressed module 21 does not contain any peptide, but contains compressed chewing gum particles containing gum base; the second compressed module 22 contains the at least one peptide, but does not contain compressed chewing gum particles containing gum base; and the third compressed module 23 does not contain any peptide, but contains compressed chewing gum particles containing gum base.
  • the tablet may, in addition to conventional chewing gum components, contain one or more components selected from the group consisting of tablet material, a taste masking agent, an absorption enhancer, a mucoadhesive agent, and combinations thereof. Such components are described in more detail infra, and may be present in the some or all of the above- mentioned compressed modules.
  • the compressed tablet contains a mucoadhesive agent and/or an absorption enhancer. While such components may be present in all or just some of the compressed modules, it is in general preferred that such components are located in the same compressed modules as the at least one peptide in order to obtain a co-release of such components.
  • conjugated is intended to indicate a heterogeneous (in the sense of composite or chimeric) molecule formed by the covalent conjugation (or attachment) of one or more peptides to one or more non-peptide moieties.
  • covalently conjugated means that the peptide and the non-peptide moiety are either directly covalently joined to one another, or else are indirectly covalently joined to one another through an intervening moiety or moieties, such as a bridge, spacer, or linkage moiety or moieties.
  • a conjugated peptide is soluble at relevant concentrations and conditions, i.e. soluble in physiological fluids such as saliva.
  • conjugated peptides of the invention include alkylated, glycosylated and/or PEGylated peptides.
  • derivative (of an peptide) is used synonymous with the term “conjugate”, i.e. a “derivative” (of an peptide) is intended to mean a heterogeneous molecule formed by the covalent conjugation (or attachment) of one or more peptides to one or more non-peptide moieties.
  • conjugation or attachment
  • derivative also covers amidated forms, acylated forms, and esterified forms of such peptides.
  • the compressed chewing gum tablet may, as discussed above, comprise one or more taste masking agents such as e.g. acids, flavours, sweeteners, etc.
  • taste masking agents such as e.g. acids, flavours, sweeteners, etc.
  • the necessity of incorporating one or more taste masking agents in the chewing gum tablet is highly dependent on the chosen peptide and to what extent the peptide has an unpleasant taste when released from the chewing gum.
  • the taste masking agent and the peptide is preferably located within the same compressed module(s). In other embodiments, it is generally preferred that the taste masking agent does not form part of the compressed chewing gum particles containing gum base, i.e. the taste masking agent is located between the compressed chewing gum particles containing gum base. This has the advantage that the peptide and the taste masking agent are co-released from the compressed chewing gum tablet upon chewing.
  • the term "co-release” means that when the peptide is released from the chewing gum during chewing, at least some taste masking agent is also released.
  • an amount of taste masking agent which is sufficient to mask the unpleasant taste of the peptide, is also released.
  • the taste-masking agent is one or more agents or compounds which, optionally together, successfully mask or cover the (potential) unpleasant taste of the peptide, but which simultaneously provides the chewing gum with a good palatability.
  • the taste masking agent is a high intensity sweetener or a flavour, optionally in combination with a polyol sweetener.
  • Useful high intensity sweeteners may be selected from the group consisting of sucralose, neotame, aspartame, salts of acesulfame in particular the potassium salt of acesulfame (acesulfame K), alitame, saccharin and its salts, cyclamic acid and its salts, glycyrrhizin, dihydrochalcones e.g. NHDC, thaumatin, monellin, stevioside, Twinsweet (aspartame-acesulfame salt) and combinations thereof.
  • the polyol sweetener is present in an amount of from 98-99.9% by weight of the total amount of taste masking agent, and the high intensity sweetener is present in an amount of from 0.1-2% by weight of the total amount of taste masking agent.
  • Suitable taste masking agents include salts of gluconate, such as sodium gluconate.
  • flavours also aid in masking potentially unpleasant flavours from various peptidic compounds.
  • pH controlling agents include organic or mineral acids (acidulants), bases, and neutralizing agents. Specific examples of such pH controlling agents include, but is not limited to, ascorbic acid, fumaric acid, adipic acid, lactic acid, malic acid, citric acid, tartaric acid, propionic acid, phosphoric acid and combinations thereof.
  • the pH controlling agent and the peptide is preferably located within the same compressed module(s).
  • the pH controlling agent does not form part of the compressed chewing gum particles containing gum base, i.e. the pH controlling agent is located between the compressed chewing gum particles containing gum base.
  • the preferred ratio of pH controlling agents in relation to the amount of incretin mimetics is 1 :6, or more preferably 2:6 and most preferably about 2:4. In other preferred embodiments, the ratio is about 1 : 10.
  • absorption enhancer As used herein, the term “absorption enhancer,” (or, analoguously, “penetration enhancer,” “permeation enhancer,” and the like) is intended to include enhancers that increase the flux of a drug across the mucosa and is limited only by functionality.
  • absorption enhancers may be selected from the group consisting of bile salts, cetomacrogols, chelating agents, citrates, cyclodextrins, detergents including steroidal detergents, enamine derivatives, fatty acids, lecithins, phospholipids, synthetic and natural surfactants including non-ionic surfactants.
  • the at least one polyterpene resin may also comprise polymerised cyclic monoterpenes, and it envisioned that the at least one polyterpene resin may consist essentially of polymerised cyclic monoterpenes.
  • the at least one polyterpene resin may further comprise polymerised limonene.
  • the at least one polyterpene resin may consist essentially of polymerised limonene.
  • the at least one polyterpene resin may also comprise polymerised alpha-pinene.
  • the at least one polyterpene resin may consist essentially of polymerised alpha- pinene.
  • the at least one polyterpene resin may comprise styrenated polyterpene resin.
  • the at least one polyterpene resin comprises at least 50% by weight polymerised cyclic monoterpenes, preferably at least 75% by weight polymerised cyclic monoterpenes, even more preferably at least 95% by weight polymerised cyclic monoterpenes.
  • the encapsulation material may comprise at least one polyvinyl acetate.
  • the encapsulation material used to encapsulate one of the components discussed above as suitably being encapsulated may comprise at least one polyterpene resin and a second encapsulation material used to encapsulate another of the components discussed above as suitably being encapsulated may comprise at least one polyvinyl acetate.
  • the method comprising the step of: a) mixing the at least one encapsulation component, e.g. food acids with at least one encapsulation material, e.g. a natural resin, b) converting the mixture of step a) to particles, thus obtaining the encapsulated component.
  • a) mixing the at least one encapsulation component e.g. food acids with at least one encapsulation material, e.g. a natural resin
  • encapsulation material e.g. a natural resin
  • Step a) may also involve mixing components such as a softening system and/or at least one elastomer with the at least one encapsulation component and the at least one encapsulation material.
  • Compression adjuvants may also be added. These compounds facilitate compression of the gum into tablets. Suitable compression adjuvants include, but are not limited to, glidants, lubricants, wetting agents, diluents, humectants. More specifically, useful compression adjuvants include silicon dioxide, magnesium stearate, calcium stearate, behenic acid, talc and similar substances which can be used to limit the tendency of the gum tablets to stick to the presses. The above mentioned chewing gum ingredients may be pre-mixed into the gum base or be added to a portion of the chewing gum comprising no or a low amount of gum base.
  • the chewing gum comprises a center filling.
  • the chewing gum tablet may be processed into in a number of different shapes such as a stick, a core, a tablet, a slab, a bead, a pellet, a tape, or a ball.
  • the chewing gum tablet may comprise a coating applied onto the chewing gum tablet.
  • a suitable coating is preferably a coating that results in extended storage stability of the compressed chewing gum products as defined above, relative to a chewing gum of the same composition that is not coated.
  • suitable coating types include hard coatings, soft coatings, film coatings and sealing coatings of any composition including those currently used in coating of chewing gum, pharmaceutical products and confectioneries.
  • the chewing gum tablet comprises the coating in an amount in the range of 1- 80% by weight of the tablet, such as in an amount in the range of 10-50%, or 15- 45% by weight of the tablet.
  • the chewing gum tablet comprises the coating in an amount in the range of 20-40% by weight of the chewing gum tablet.
  • the coating may be a hard coating, which term is used in the conventional meaning of that term including sugar coatings and sugar-free (or sugarless) coatings and combinations thereof.
  • the objects of hard coating are to obtain a sweet, crunchy layer, which is appreciated by the consumer, and to protect the composition for various reasons.
  • the gum tablets are successively treated in suitable coating equipment with aqueous solutions of crystallizable sugar and/or polyols such as sucrose or dextrose, which, depending on the stage of coating reached, may contain other functional ingredients, e.g. fillers, colours, etc.
  • the sugar coating may contain further functional or active compounds including flavour compounds, peptides and/or other therapeutically active compounds.
  • peptides suitable for use in connection with the present invention include any peptidic compound with a therapeutic potential.
  • peptides examples include: incretin mimetics, exendins, Liraglutide (Novo Nordisk), ZP-IO (Zealand Pharma), MC-4 Antagonists, PYY (3-36), Tesofensine (Neurosearch), Obinepitide (7TM Pharma), TM30339 (7TM Pharma), RHS08 (Rheoscience), vasopressin, a vasopressin polypeptide analog, desmopressin, glucagon, corticotropin, gonadotropin, C- peptide of insulin, parathyroid hormone, human growth hormone, growth hormone, growth hormone releasing hormone, oxytocin, corticotropin releasing hormone, somatostatin, a somatostatin polypeptide analog, gonadotropin agonist, a gonadotropin agonist polypeptide analog, atrial natriuretic peptide, thyroxine releasing hormone, follicle stimulating ho[pi]none, prolactin, growth factors, interleukin
  • interferon-beta INF-. beta.
  • interferon-gamma INF- . gamma.
  • human growth hormone hGH
  • exenatide glucagon-like peptide-1
  • GLP-2 glucagon-like peptide-2
  • glucagon-like peptide-1 derivatives oxytocin, insulin and carbetocin.
  • the peptides are preferably of a length of about 6-4000 amino acids, more preferably about 8-2000 amino acids, more preferably about 8-1000 amino acids, more preferably about 8-500 amino acids, more preferably about 8-250 amino acids, more preferably about 8-200 amino acids, more preferably about 8- 175 amino acids, more preferably about 8-150 amino acids, more preferably about 8-125 amino acids, more preferably about 8-100 amino acids, more preferably about 8-75 amino acids, and most preferably about 8-50 amino acids, and most preferably about 8-30 amino acids.
  • the present invention relates to use of a tablet according to the present invention for use as a medicament.
  • the present invention relates to use of a tablet according to the present invention for the manufacture of a chewing gum tablet for prevention and/or amelioration of dental plaque.
  • the present invention relates to a method for the treatment of, or ameliorating the symptoms of, dental plaques, said method comprising administering a tablet according to the present invention to a patient in need thereof.
  • the amount of incretin mimetic being transferred from the tablet to the blood stream is about 1- 25% of the amount in the tablet.
  • the remaining 75-99% of the peptide in the tablet is either retained in the chewing gum and/or swallowed and digested.
  • Preferably about 2-15% of the peptide is transferred to the blood stream, more preferably 3-10%, and most preferably 5-8%.
  • the premixture is mixed dry in a conventional dry mixer.
  • each layer including the premixture is mixed dry in a conventional dry mixer and formed into a tablet in a tablet machine:
  • Chewing gum mixture I is passed to a standard tablet pressing machine comprising dosing apparatus (e.g. P 3200 C, available from Fette GmbH, Germany) and compressed to form a first compressed module. Subsequent, mixture II is filed into the tablet pressing machine and compressed onto the first module to form a chewing gum tablet having two compressed modules.
  • dosing apparatus e.g. P 3200 C, available from Fette GmbH, Germany
  • the content of KSL-W is 4 mg per piece and CPC 0,8 mg per piece. If a tablet with a higher or lower content af KSL-W and CPC is desired, the amounts of KSL-W, CPC and sorbitol are adjusted correspondingly.
  • the apparatus is composed of a temperature controlled chewing chamber with two horizontal pistons and one vertical piston.
  • the chewing gum tablets obtained in example 1 are packed in commercial packages (blister packs, Duma bottles and/or aluminium bags) and stored for up to 3 months at conditions 40°C/75% RH and 21°C/55% RH.
  • the amount of exenatide is measured at the beginning of the storage (initial amount) and after 1, 2 and 3 months.

Abstract

La présente invention concerne des compositions de chewing-gum comprimé contenant un médicament et, en particulier, des compositions de chewing-gum comprimé contenant un peptide, par exemple des peptides à activité antimicrobienne.
PCT/DK2007/050198 2007-12-20 2007-12-20 Chewing-gum comprimé contenant un peptide WO2009080023A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PCT/DK2007/050198 WO2009080023A1 (fr) 2007-12-20 2007-12-20 Chewing-gum comprimé contenant un peptide
PCT/DK2008/000444 WO2009080032A1 (fr) 2007-12-20 2008-12-19 Chewing-gum comprimé comprenant un petit peptide à action systémique

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/DK2007/050198 WO2009080023A1 (fr) 2007-12-20 2007-12-20 Chewing-gum comprimé contenant un peptide

Publications (1)

Publication Number Publication Date
WO2009080023A1 true WO2009080023A1 (fr) 2009-07-02

Family

ID=39712736

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2007/050198 WO2009080023A1 (fr) 2007-12-20 2007-12-20 Chewing-gum comprimé contenant un peptide

Country Status (1)

Country Link
WO (1) WO2009080023A1 (fr)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019219144A1 (fr) * 2018-05-17 2019-11-21 Fertin Pharma A/S Comprimé oral à désintégration approprié pour des principes actifs pharmaceutiques
WO2019219145A1 (fr) * 2018-05-17 2019-11-21 Fertin Pharma A/S Comprimé oral approprié pour une libération rapide d'ingrédients pharmaceutiques actifs
WO2019219147A1 (fr) * 2018-05-17 2019-11-21 Fertin Pharma A/S Gomme à mâcher en comprimés appropriée pour des ingrédients pharmaceutiques actifs
US10543205B2 (en) 2016-11-18 2020-01-28 Fertin Pharma A/S Oral delivery vehicle containing nicotine
US10632076B2 (en) 2016-11-18 2020-04-28 Fertin Pharma A/S Tablet comprising separate binder and erythritol
US11058641B2 (en) 2018-05-17 2021-07-13 Fertin Pharma A/S Oral tablet for taste masking of active ingredients
US11090263B2 (en) 2018-05-22 2021-08-17 Fertin Pharma A/S Tableted chewing gum suitable for active pharmaceutical ingredients
US11096895B2 (en) 2018-05-17 2021-08-24 Fertin Pharma A/S Oral tablet suitable for active pharmaceutical ingredients
US11096896B2 (en) 2018-05-17 2021-08-24 Fertin Pharma A/S Tablet dosage form for buccal absorption of active ingredients
US11096894B2 (en) 2018-05-17 2021-08-24 Fertin Pharma A/S Oral tablet for induced saliva generation
US11135157B2 (en) 2018-05-17 2021-10-05 Fertin Pharma A/S Oral tablet for delivery of active ingredients to the throat
CN113717247A (zh) * 2021-08-31 2021-11-30 哈尔滨吉象隆生物技术有限公司 一种抗细菌多肽及其应用
US11260030B2 (en) 2018-05-17 2022-03-01 Fertin Pharma A/S Oral tablet for delivery of active ingredients to the gastrointestinal tract
US20220183992A1 (en) * 2019-03-07 2022-06-16 Terpene Therapeutics Inc. Edible Film Comprising Adjacent Conjoined Strips
CH718673A1 (fr) * 2021-05-28 2022-11-30 Vixelia Compositions de soins bucco-dentaires.

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006002622A1 (fr) * 2004-07-06 2006-01-12 Gumlink A/S Tablette comprimee de chewing gum
WO2006079343A1 (fr) * 2005-01-28 2006-08-03 Gumlink A/S Comprime de gomme a macher compressee
WO2007047899A2 (fr) * 2005-10-18 2007-04-26 The U.S. Government As Represented By The Secreatary Of The Army Traitement d'hygiene buccale aux decapeptides antimicrobiens
WO2007140286A2 (fr) * 2006-05-25 2007-12-06 Wm. Wrigley Jr. Company Compositions orales permettant d'éliminer efficacement les taches sur les dents

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006002622A1 (fr) * 2004-07-06 2006-01-12 Gumlink A/S Tablette comprimee de chewing gum
WO2006079343A1 (fr) * 2005-01-28 2006-08-03 Gumlink A/S Comprime de gomme a macher compressee
WO2007047899A2 (fr) * 2005-10-18 2007-04-26 The U.S. Government As Represented By The Secreatary Of The Army Traitement d'hygiene buccale aux decapeptides antimicrobiens
WO2007140286A2 (fr) * 2006-05-25 2007-12-06 Wm. Wrigley Jr. Company Compositions orales permettant d'éliminer efficacement les taches sur les dents

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FARAJ ET AL.: "Development of a Peptide-containing Chewing Gum as a Sustained Release Antiplaque Antimicrobial Delivery System", AAPS PHARMSCITECH, vol. 8, no. 1, 30 March 2007 (2007-03-30), pages E1 - E9, XP002494327 *
NA ET AL: "Chewing gum of antimicrobial decapeptide (KSL) as a sustained antiplaque agent: Preformulation study", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 107, no. 1, 20 September 2005 (2005-09-20), pages 122 - 130, XP005064066, ISSN: 0168-3659 *

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10632076B2 (en) 2016-11-18 2020-04-28 Fertin Pharma A/S Tablet comprising separate binder and erythritol
US11484503B2 (en) 2016-11-18 2022-11-01 Fertin Pharma A/S Tablet comprising separate binder and erythritol
US11351162B2 (en) 2016-11-18 2022-06-07 Fertin Pharma A/S Oral delivery vehicle containing flavoring agents
US10543205B2 (en) 2016-11-18 2020-01-28 Fertin Pharma A/S Oral delivery vehicle containing nicotine
JP2021524442A (ja) * 2018-05-17 2021-09-13 フェルティン ファルマ アー／エス 医薬品活性成分に適した錠剤化チューインガム
AU2019268497B2 (en) * 2018-05-17 2022-01-06 Fertin Pharma A/S A tableted chewing gum suitable for active pharmaceutical ingredients
US11058641B2 (en) 2018-05-17 2021-07-13 Fertin Pharma A/S Oral tablet for taste masking of active ingredients
US11058633B2 (en) 2018-05-17 2021-07-13 Fertin Pharma A/S Disintegrating oral tablet suitable for active pharmaceutical ingredients
JP7214755B2 (ja) 2018-05-17 2023-01-30 フェルティン ファルマ アー／エス 医薬品活性成分に適した錠剤化チューインガム
US11096895B2 (en) 2018-05-17 2021-08-24 Fertin Pharma A/S Oral tablet suitable for active pharmaceutical ingredients
US11096896B2 (en) 2018-05-17 2021-08-24 Fertin Pharma A/S Tablet dosage form for buccal absorption of active ingredients
US11096894B2 (en) 2018-05-17 2021-08-24 Fertin Pharma A/S Oral tablet for induced saliva generation
WO2019219144A1 (fr) * 2018-05-17 2019-11-21 Fertin Pharma A/S Comprimé oral à désintégration approprié pour des principes actifs pharmaceutiques
US11135157B2 (en) 2018-05-17 2021-10-05 Fertin Pharma A/S Oral tablet for delivery of active ingredients to the throat
WO2019219145A1 (fr) * 2018-05-17 2019-11-21 Fertin Pharma A/S Comprimé oral approprié pour une libération rapide d'ingrédients pharmaceutiques actifs
US11052047B2 (en) 2018-05-17 2021-07-06 Fertin Pharma A/S Oral tablet suitable for fast release of active pharmaceutical ingredients
US11260030B2 (en) 2018-05-17 2022-03-01 Fertin Pharma A/S Oral tablet for delivery of active ingredients to the gastrointestinal tract
RU2770035C1 (ru) * 2018-05-17 2022-04-14 Фертин Фарма А/С Таблетированная жевательная резинка, подходящая для активных фармацевтических ингредиентов
AU2019268496B2 (en) * 2018-05-17 2022-06-02 Fertin Pharma A/S An oral tablet suitable for active pharmaceutical ingredients comprising non-directly compressible sugar alcohol particles
WO2019219147A1 (fr) * 2018-05-17 2019-11-21 Fertin Pharma A/S Gomme à mâcher en comprimés appropriée pour des ingrédients pharmaceutiques actifs
AU2019269879B2 (en) * 2018-05-17 2022-07-21 Fertin Pharma A/S An oral tablet for induced saliva generation
US11090263B2 (en) 2018-05-22 2021-08-17 Fertin Pharma A/S Tableted chewing gum suitable for active pharmaceutical ingredients
US20220183992A1 (en) * 2019-03-07 2022-06-16 Terpene Therapeutics Inc. Edible Film Comprising Adjacent Conjoined Strips
CH718673A1 (fr) * 2021-05-28 2022-11-30 Vixelia Compositions de soins bucco-dentaires.
WO2022248533A1 (fr) * 2021-05-28 2022-12-01 Vixelia Sàrl Compositions de soins bucco-dentaires
CN113717247A (zh) * 2021-08-31 2021-11-30 哈尔滨吉象隆生物技术有限公司 一种抗细菌多肽及其应用

Similar Documents

Publication Publication Date Title
WO2009080023A1 (fr) Chewing-gum comprimé contenant un peptide
WO2009080032A1 (fr) Chewing-gum comprimé comprenant un petit peptide à action systémique
WO2009080024A1 (fr) Chewing-gum comprimé comprenant un mimétique de l'incrétine
EP2361081B1 (fr) Forme posologique intra-orale à parties multiples et son utilisation
JP2022088537A (ja) 新規経口投与製剤
EP2229157B1 (fr) Tablette de chewing gum comprimé
EP2229156B1 (fr) Tablette de chewing-gum et procédés de dosage des principes pharmaceutiquement actifs de ladite tablette de chewing-gum
RU2476221C2 (ru) Состав, содержащий никотин, с покрытием для перорального применения с буферными свойствами, приданными аминокислотой
US20100247586A1 (en) Multi-Portion Intra-Oral Dosage Form With Organoleptic Properties
US20100124560A1 (en) Multi portion intra-oral dosage form and use thereof
WO2007096906A2 (fr) Nouvelles compositions bucco-adhésives et procédé d'élaboration desdites compositions
JPH04312532A (ja) アセチルサリチル酸を含有する薬用チユーインガム
HUE035266T2 (en) As a buffer, a pharmaceutical product containing trometamol for oral administration of nicotine
EP2229158A1 (fr) Tablette de chewing-gum comprimé
CN110621307A (zh) 含有烟碱的口香糖组合物
ES2966539T3 (es) Comprimido oral de cannabinoides
DK2373179T3 (en) MULTIPLE KIT comprising a chewing gum and a further flavoring-containing formulation
WO2009080033A1 (fr) Chewing-gum comprimé comprenant de la metformine
AU2006228949A1 (en) Compositions for oral transmucosal delivery of metformin
JP2023164671A (ja) 低中毒性抗コリン作動性エステルのための方法および組成物
WO2010063756A1 (fr) Formulations pour administration buccale systémique comprenant la s- adénosylméthionine, leur préparation et utilisation
Jaiswal Oral strip technology: A review
AU2004273574B2 (en) Buccal formulations of galanthamine and uses thereof
CA3037040A1 (fr) Compositions de finasteride et de sildenafil et applications
Lakkis Encapsulation and controlled release applications in confectionery and oral care products

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07846458

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07846458

Country of ref document: EP

Kind code of ref document: A1